SNY
Sanofi
NASDAQ · Healthcare · Drug Manufacturers - General · FR
$44.24
−0.20%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 48.9B | 46.7B | 44.3B | 41.6B | 40.6B |
| Cost of Revenue | 13.2B | 13.0B | 13.2B | 12.6B | 11.9B |
| Gross Profit | 35.7B | 33.7B | 31.1B | 29.0B | 28.7B |
| Operating Expenses | |||||
| R&D Expense | 8.1B | 7.8B | 7.4B | 6.5B | 6.5B |
| SG&A Expense | 9.8B | 10.2B | 9.2B | 8.9B | 8.7B |
| General & Admin Expense | 4.8B | 9.5B | — | — | — |
| Selling & Marketing Expense | 336.0M | 699.0M | — | — | — |
| Other Expenses | 10.6B | 6.0B | 7.3B | 6.6B | 3.3B |
| Total Operating Expenses | 28.5B | 24.1B | 23.8B | 22.0B | 18.5B |
| Cost and Expenses | 41.7B | 37.1B | 37.0B | 34.7B | 30.4B |
| Operating Income (EBIT) | 7.2B | 9.6B | 7.3B | 7.0B | 10.2B |
| Non-Operating | |||||
| Interest Income | 274.7M | 331.0M | 457.5M | 530.5M | 169.0M |
| Interest Expense | 591.4M | 626.0M | 622.6M | 512.8M | 384.8M |
| Net Interest Income | (316.7M) | (295.0M) | (165.0M) | 17.7M | (215.8M) |
| Other Non-Op Income/Expense | (2.0B) | (3.6B) | (494.0M) | (845.0M) | (170.0M) |
| Non-Operating Income (excl Interest) | (1.7B) | 2.8B | (195.0M) | (1.0M) | (240.0M) |
| EBT (Pre-Tax Income) | 5.2B | 6.0B | 6.8B | 6.1B | 10.0B |
| Income Tax Expense | 1.2B | 1.0B | 1.2B | 1.0B | 1.9B |
| Bottom Line | |||||
| Net Income | 4.0B | 7.8B | 5.6B | 5.4B | 8.4B |
| Earnings from Cont. Ops | 4.0B | 5.0B | 5.6B | 5.1B | 8.1B |
| Earnings from Discont. Ops | 19.0M | 2.9B | 64.0M | 338.0M | 401.0M |
| Bottom Line Net Income | 1.1B | 7.8B | 5.6B | 5.4B | 8.4B |
| Per Share | |||||
| Basic EPS | $0.48 | $3.20 | $2.19 | $2.15 | $3.19 |
| Diluted EPS | $0.49 | $3.20 | $2.19 | $2.15 | $3.18 |
| Revenue Per Share | $20.44 | $19.14 | $17.69 | $16.62 | $16.20 |
| Shares | |||||
| Basic Shares Outstanding | 2.4B | 2.4B | 2.5B | 2.5B | 2.5B |
| Diluted Shares Outstanding | 2.4B | 2.4B | 2.5B | 2.5B | 2.5B |
| Profitability Metrics | |||||
| EBITDA | 12.4B | 12.5B | 11.0B | 11.4B | 13.5B |
| D&A | 3.5B | 5.7B | 3.6B | 4.4B | 3.1B |
| EBIT | 8.9B | 6.8B | 7.4B | 7.0B | 10.4B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026